Krystal Biotech receives FDA approval for innovative gene therapy drug
Krystal Biotech Inc. announced that the U.S. Food and Drug Administration approved the use of VYJUVEK to treat dystrophic epidermolysis bullosa (DEB) for patients who are six months of age or older. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - May 19, 2023 Category: American Health Authors: Nate Doughty Source Type: news

FDA Approves First-Ever Topical Gene Therapy FDA Approves First-Ever Topical Gene Therapy
The topical treatment will be used to treat wounds in patients with dystrophic epidermolysis bullosa.Medscape Medical News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - May 19, 2023 Category: Drugs & Pharmacology Tags: Dermatology News Alert Source Type: news

Rare Skin Blistering Condition Gets First Drug Approved
(MedPage Today) -- Credit: B.E.L.A. butterfly children The FDA granted the first drug approval for dystrophic epidermolysis bullosa (DEB), a topical gene therapy that treats the blistering wounds it causes, the agency announced Friday. The... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - May 19, 2023 Category: American Health Source Type: news

FDA Approves Vyjuvek (beremagene geperpavec-svdt) Redosable Gene Therapy for the Treatment of Dystrophic Epidermolysis Bullosa
PITTSBURGH, May 19, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the Company) (NASDAQ: KRYS), a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases, today announced the US Food and... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - May 19, 2023 Category: Drugs & Pharmacology Source Type: news

Topical Gene Therapy Gel Heals Dystrophic EB Wounds Topical Gene Therapy Gel Heals Dystrophic EB Wounds
The first topical in vivo gene therapy to reach late-stage development heals dystrophic epidermolysis bullosa wounds, researchers report.Medscape Medical News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - January 26, 2023 Category: Drugs & Pharmacology Tags: Dermatology News Source Type: news

Topical Gene Therapy Heals Blistering Skin Disease Lesions
(MedPage Today) -- A novel topical gene therapy healed most lesions among patients with dystrophic epidermolysis bullosa, a rare genetic blistering skin disease, the GEM-3 trial showed. Topical administration of beremagene geperpavec (B-VEC) led... (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - December 14, 2022 Category: Dermatology Source Type: news

Topical Gel for Epidermolysis Bullosa Shows Ongoing Benefit Topical Gel for Epidermolysis Bullosa Shows Ongoing Benefit
Patients with EB experienced substantial reductions in affected skin area with continued use of the bark-derived topical agent oleogel-S10 in an open-label extension study.Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - July 12, 2022 Category: Dermatology Tags: Dermatology News Source Type: news

Topical Treatment for EB Recommended for Approval in the EU Topical Treatment for EB Recommended for Approval in the EU
In February, the FDA declined to approve the company ' s new drug application as it was presented and asked the company to submit additional evidence of effectiveness for epidermolysis bullosa (EB).International Approvals (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - April 27, 2022 Category: Dermatology Tags: Dermatology News Alert Source Type: news

Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa
This review discusses the principles of gene therapy and its application to recessive dystrophic epidermolysis bullosa, the most debilitating variant of EB. Where does current research stand?The British Journal of Dermatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 26, 2022 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news

Woman with condition that causes blisters and sores shows them off in sexy photos
Fernanda Tanajura, from Brazil, was born with a rare genetic condition called epidermolysis bullosa, which causes the skin to become paper thin. (Source: the Mail online | Health)
Source: the Mail online | Health - July 12, 2021 Category: Consumer Health News Source Type: news

Artificial intelligence provides faster diagnosis for debilitating blistering disease
(University of Groningen) Scientists at the University of Groningen have trained an Artificial Intelligence system to recognize a specific pattern in skin biopsies of patients with the blistering disease epidermolysis bullosa acquisita. The pattern is characteristic of a specific variant of the disease which can cause scarring of the skin and mucous membranes, and may lead to blindness. The new system is easy to use and is better than most doctors in making the diagnosis. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 8, 2021 Category: International Medicine & Public Health Source Type: news

Characterizing Common Wound Microbes in Epidermolysis Bullosa Characterizing Common Wound Microbes in Epidermolysis Bullosa
Wound cultures from patients with epidermolysis bullosa were most frequently positive for Staphylococcus aureus, Pseudomonas aeruginosa, and Streptococcus pyogenes; antibiotic resistance was common.Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - January 7, 2021 Category: Dermatology Tags: Dermatology News Source Type: news

Birch Bark Derivative Effective for Epidermolysis Bullosa Birch Bark Derivative Effective for Epidermolysis Bullosa
Oleogel-S10 closed target wounds faster than placebo in 58-site, 28-country phase 3 study. This is the first topical medication ever tested for epidermolysis bullosa to beat placebo.Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 2, 2020 Category: Consumer Health News Tags: Dermatology News Source Type: news

FDA Grants Fast Track Status to Aegle Therapeutics' AGLE-102 for the Treatment of Dystrophic Epidermolysis Bullosa
BOSTON and MIAMI, Oct. 1, 2020 -- (Healthcare Sales & Marketing Network) -- Aegle Therapeutics Corporation today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to AGLE-102™ for the treatment of patients with dyst... Biopharmaceuticals, Dermatology, FDA Aegle Therapeutics, Dystrophic Epidermolysis Bullosa (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 21, 2020 Category: Pharmaceuticals Source Type: news

Foot Care in Epidermolysis Bullosa: Evidence-based Guideline Foot Care in Epidermolysis Bullosa: Evidence-based Guideline
This article presents an evidence-based set of current best practice guidelines regarding foot care in patients with EB.The British Journal of Dermatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 27, 2020 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news